In vitro study demonstrates potent activity of nitroxoline against Aspergillus isolates, suggesting repurposing potential for drug-resistant fungal infections.
BACKGROUND: Nitroxoline is an old antibiotic currently approved for the treatment of uncomplicated urinary tract infections. Its mode of action is based on the chelation of bivalent cations, such as zinc. OBJECTIVES: As zinc plays a central role in the metabolism of Aspergillus spp., we performed antifungal susceptibility testing against Nitroxoline using broth microdilution. METHODS: Overall, 13 Aspergillus isolates were tested according to the EUCAST guidance document (Guinea et al. EUCAST, def. doc. 9.4, 2022) including two genetically proven Azole-resistant strains. RESULTS: was 0.5 mg/L. CONCLUSIONS: These results correspond to excellent in vitro activity against Aspergillus spp.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: